Benign Prostatic Hyperplasia Newswire (Page 8)

Benign Prostatic Hyperplasia Newswire (Page 8)

Comprehensive Real-Time News Feed for Benign Prostatic Hyperplasia. (Page 8)

Results 141 - 160 of 750 in Benign Prostatic Hyperplasia

  1. Medifocus Announces The Engagement Of As Lead Designer Of Next...Read the original story

    Jan 11, 2016 | BioSpace

    Medifocus, Inc. a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia and Breast Cancer, and Heat Activated Tumor Targeted Immunotherapy and Gene Therapy, today announced that the Company has engaged Tanaka Kapec Design Group, Inc. as lead designer for the Company's next generation Prolieve Thermodilatation System for treatment of BPH. BPH is a medical condition that affects over 50% of men over the age of 50, and a large percentage of them will not meet treatment goals on oral medication alone.

    Comment?

  2. Nymox Pharmaceutical Corp (NYMX) Director Purchases $275,500.00 in StockRead the original story w/Photo

    Jan 8, 2016 | AmericanBankingNews.com

    ... company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ( NASDAQ:NYMX ) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests ...

    Comment?

  3. SPINK1 Promoter Variants Are Associated with Prostate Cancer...Read the original story

    Jan 5, 2016 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Background/Aim: Several studies reported that patients with benign prostatic hyperplasia experienced a 10% increased incidence of prostate cancer after the first 5 years of diagnosis.

    Comment?

  4. Decongestants sometimes cause more harm than goodRead the original story

    Jan 1, 2016 | Holtville Tribune

    ... kind but can still cause problems. People who have conditions such as diabetes, benign prostatic hyperplasia (BPH), ischemic heart problems, thyroid disorders, glaucoma and seizures generally should avoid using nasal decongestants. In addition, ...

    Comment?

  5. Medifocus Announces Grant Of Incentive Options And Completion Of Shares For Debt TransactionRead the original story

    Dec 30, 2015 | BioSpace

    ... this fact to improve clinical outcome. Its ProlieveA Thermodilatation System offers relief from Benign Prostatic Hyperplasia (BPH) to millions of men with a simple, 45-minute, in-office treatment. Its APA 1000 Breast Cancer Treatment System is ...

    Comment?

  6. James George Robinson Buys 6,000 Shares of Nymox Pharmaceutical Corp (NYMX) StockRead the original story w/Photo

    Dec 30, 2015 | AmericanBankingNews.com

    ... company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ( NASDAQ:NYMX ) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests ...

    Comment?

  7. Optiprostate xts review: How does optiprostate xts work?Read the original story w/Photo

    Dec 21, 2015 | Examiner.com

    What exactly is optiprostate xts? OptiProstate XTS is a top of the line supplement made specifically for men suffering from Benign Prostatic Hyperplasia , better known as an enlarged prostate . In contains a synergistic blend of ingredients, which in addition to alleviating the discomfort of a swollen prostate, will also relieve accessory symptoms, such as the annoying need to urinate frequently.

    Comment?

  8. Nymox Pharmaceutical Corp (NYMX) Director James George Robinson Acquires 63,334 SharesRead the original story w/Photo

    Dec 19, 2015 | AmericanBankingNews.com

    ... company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ( NASDAQ:NYMX ) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests ...

    Comment?

  9. OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity...Read the original story

    Dec 19, 2015 | Emailwire.com

    Researchmoz added Most up-to-date research on "OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024" to its huge collection of research reports. GlobalData estimates the 2014 sales for the benign prostatic hyperplasia therapeutics market at approximately $2 billion across the 7MM .

    Comment?

  10. Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024: Market Opportunity AnalyzerRead the original story w/Photo

    Dec 18, 2015 | SBWire

    Research estimates the 2014 sales for the benign prostatic hyperplasia therapeutics market at approximately $2 billion across the 7MM . The US contributed a significant majority of these sales, generating an estimated $1.15 billion over the forecast period, ending in 2024.

    Comment?

  11. SOM Biotech Is Launching An Indiegogo Crowdfunding Campaign For Pediatric Rare DiseasesRead the original story

    Dec 15, 2015 | BioSpace

    ... Huntington's disease and glioblastoma) to other therapeutic areas (Alzheimer's disease and benign prostatic hyperplasia). For further information: Please visit our Indiegogo campaign page: http://igg.me/at/fightrarediseases Alternatively, inquiries ...

    Comment?

  12. PSA Testing Market - Global Industry Analysis, Size, Trends and Forecast, 2013 - 2019Read the original story w/Photo

    Dec 16, 2015 | SBWire

    ... observed in cases of prostate cancer or other prostate related diseases such as prostatitis or benign prostatic hyperplasia. PSA liquefies the semen in the seminal coagulum and allows sperm to swim freely. It is also believed to dissolve the ...

    Comment?

  13. Recent Research Analysts' Ratings Updates for AEterna ZentarisRead the original story w/Photo

    Dec 14, 2015 | AmericanBankingNews.com

    ... focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The ...

    Comment?

  14. Nymox Pharmaceutical Corp (NYMX) Director James George Robinson Acquires 46,812 SharesRead the original story w/Photo

    Dec 12, 2015 | AmericanBankingNews.com

    ... company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ( NASDAQ:NYMX ) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests ...

    Comment?

  15. Know the signs, detect prostate cancer early.Read the original story

    Dec 9, 2015 | Menlo Park City Council

    ... 1988. Some of this increase was probably due to the popularity of transurethral resection for benign prostatic hyperplasia (BPH) and the resulting incidental diagnosis of prostate cancer. In the late 1980s the introduction of prostate-specific ...

    Comment?

  16. No Right Answer [Circulation Cardiovascular Case Series]Read the original story

    Dec 7, 2015 | Circulation

    ... H is a 61-year-old man with a medical history significant for hypertension, hyperlipidemia, and benign prostatic hyperplasia who was admitted to the medical service with a chief complaint of fevers. Eleven years before presentation, the patient ...

    Comment?

  17. Stroke risk for older men who take alpha-blockersRead the original story w/Photo

    Dec 7, 2015 | Medical News Today

    ... they did not include 5-alpha-reductase inhibitors - which is an alternative treatment for benign prostatic hyperplasia. Finally, because the study was carried out mainly among Chinese men in Taiwan, the team says further research is needed to ...

    Comment?

  18. Nymox Pharmaceutical Corp (NYMX) Director Purchases $378,400.00 in StockRead the original story w/Photo

    Dec 5, 2015 | AmericanBankingNews.com

    ... company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ( NASDAQ:NYMX ) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests ...

    Comment?

  19. PROCEPT Biorobotics Announces First Patients Treated In Global IDE Clinical Trial For BPHRead the original story

    Dec 3, 2015 | BioSpace

    The AquaBeam System combines image guidance and robotics to deliver Aquablation, a waterjet ablation therapy that enables targeted, controlled, and heat-free removal of the tissue for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia , a common prostate problem affecting more than 50% of men over 50 years in age. The WATER study is a prospective randomized U.S. investigational device exemption clinical trial for male patients between the ages of 45 and 80 years old who have urinary symptoms due to BPH.

    Comment?

  20. OncBioMune Pharmaceuticals, Inc. (OBMP) is "One to Watch"Read the original story

    Dec 4, 2015 | InvestorIdeas.com

    ... where the prostate enlarges on its own, which is almost inevitable in men as they age, known as benign prostatic hyperplasia (BPH). However, even with the emergence of five new drugs since 2010 from players like Dendreon (OTC: DNDNQ) and Medivation ...

    Comment?